CDKN2B and central nervous system cancer: A case-control study recruited 855 high-grade glioma patients from four different geographic regions of the US and belonging to five inherited glioma risk variants: 5p15.3 (TERT), 8q24.21 (CCDC26/MLZE), 9p21.3 (CDKN2B), 11q23.3 (PHLDB1/DDX6) and 20q13.3 (RTEL1) [24].